

**Table 1. Clinical data of the MS and control cases used in this study**

	Case	Sex	Age, years	PMD, hours	Disease duration, years	Cause of death	Course	Lesions analyzed				
								Active	Chronic active	Chronic silent	Shadow plaques	NAWM
MS												
	<b>MS47</b>	F	66	17	34	Multiple sclerosis	SP		1			
	<b>MS49</b>	M	75	8	38	Aspiration pneumonia, cerebrovascular accident, MS	RR		1			
	<b>MS54</b>	F	69	11	31	Acute pyelonephritis, hydronephrosis, MS	PP				1	
	<b>MS55</b>	F	47	15	32	Pneumonia	SP	1				1
	<b>MS56</b>	M	63	11	39	Pneumonia, MS	SP					1
	<b>MS57</b>	F	77	9	31	General deterioration, lung infection, treatment withheld	PP			2	1	1
	<b>MS58</b>	F	51	15	21	MS	SP	1				1
	<b>MS74</b>	F	64	7	36	Gastrointestinal bleed/obstruction, aspiration pneumonia	SP	1	1			

							Lesions analyzed				
<b>MS79</b>	F	49	7	21	Bronchopneumonia , MS	SP	3	2			1
<b>MS92</b>	F	37	26	17	MS	SP	1	1			
<b>MS100</b>	M	46	7	8	Pneumonia	SP		1			
<b>MS106</b>	F	39	18	21	Bronchopneumonia	PP		1			
<b>MS107</b>	M	38	19	>16	Aspiration pneumonia, pulmonary edema	RP	1			1	
<b>MS127</b>	M	51	21	10	MS, bronchopneumonia	SP	1	1			
<b>MS136</b>	M	50	10	9	Respiratory failure, sepsis, MS	SP	2	2			
<b>MS153</b>	F	50	12	NS	MS	SP		1			
<b>MS154</b>	F	34	12	9	Pneumonia	SP	1	1			
<b>Control</b>											
<b>C20</b>	F	84	24		Congestive cardiac failure						
<b>C05</b>	F	95	10		Bronchopneumonia						
<b>1026</b>	M	44	NS		Cirrhose						
<b>1152</b>	M	27	NS		Embolie pulmonaire						
<b>1154</b>	F	43	NS		Overdose						

PMD, postmortem delay; NS, not specified; PP, primary progressive; SP, secondary progressive; RR, relapsing-remitting; RP, relapsing progressive.